GE Healthcare, Merck Collaborating on Lung Imaging Tech Trial | GenomeWeb
NEW YORK (GenomeWeb News) – GE Healthcare said today it has signed an agreement giving the drugmaker Merck access to a molecular imaging agent GE is developing for high-speed, quantitative lung imaging.
 
The company said the collaborators will evaluate GE Healthcare’s Spin Signal Technology to determine if it can help researchers study the functioning of diseased lungs using modified xenon gas in conjunction with magnetic resonance imaging scans.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.